Patent classifications
C07K5/10
Nitrogen-containing compound or salt thereof, or metal complex thereof
The present invention provides a compound represented by the formula (1) or a salt thereof, or a complex of the compound or the salt with a metal, in the formula (1), A.sup.1 represents a chelate group; R.sup.1 represents a hydrogen atom or the like; R.sup.2 represents a hydrogen atom or the like; and Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, and Z.sup.5 are the same or different and each represent a nitrogen atom or CR.sup.3 or the like wherein R.sup.3 represents a hydrogen atom or an optionally substituted C.sub.1-6 alkyl group or the like; L.sup.1 represents a group represented by the formula (3) wherein R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are the same or different and each represent a hydrogen atom or the like; L.sup.2 represents an optionally substituted C.sub.1-6 alkylene group; and L.sup.3 represents an optionally substituted C.sub.1-6 alkylene group. ##STR00001##
Methods And Compositions For Stimulating Collagen Synthesis In Skin Cells
A composition comprising a first peptide selected from tripeptide, tetrapeptide and mixtures thereof; a second peptide selected from pentapeptide, hexapeptide, and mixtures thereof; an extract from the Laminaria genus, and whey protein, and a method for stimulating collagen synthesis in skin cells.
CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Peptides and compositions for use in cosmetics
A family of peptides with antioxidant and brightening activities is disclosed as well as cosmetic compositions having the peptides and cosmetic uses and methods of the peptides or cosmetic compositions.
Peptoids useful for the mineralization of apatite
The present invention provides for a bio-mimetic polymer capable of catalyzing or mineralizing calcium ion and phosphate ions into an apatite.
MITOCHONDRIA-TARGETING PEPTIDES
Disclosed are analogs of SBT-20. The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
HAIR TREATMENT COMPOSITION, METHODS AND USES THEREOF
The present disclosure relates to a composition comprising a general ionic liquid, a eutectic mixture or a deep eutectic mixture as a solvent and at least one soluble auxiliary substance. The auxiliary substance might be a peptide or reducing agent or a surfactant or cosmetic component or a combination of them, with the purpose to modify the characteristics of human hair.
Cyclic peptides as protein targeting agents
Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): ##STR00001##
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R.sup.1, L.sup.1, L.sup.2, G, M, Y.sup.1Y.sup.2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
Cyclic peptides as protein targeting agents
Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): ##STR00001##
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R.sup.1, L.sup.1, L.sup.2, G, M, Y.sup.1Y.sup.2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.